Research Technological Partnership: PITE-FAPESP Consortium
The São Paulo Research Foundation (FAPESP), Drugs for Neglected Diseases initiative (DNDi), Medicines for Malaria Venture (MMV), University of São Paulo (USP) and University of Campinas (UNICAMP) invite you to the launch of the project
Research Partnership for Technological Innovation (PITE-FAPESP)
to discover novel drug candidates for the treatment
of parasitic tropical diseases
November 28th, 2019 • 9:30 – 11:05 • FAPESP
The event will present the PITE FAPESP Consortium to be based at the University of Campinas (UNICAMP). The project will be carried out in partnership with the leading institutions mentioned above. The ultimate goal is to discover new drug candidates for clinical development in the treatment of parasitic tropical diseases.
PITE AGREEMENT ANNOUNCEMENT
PITE–FAPESP Consortium MMV/DNDi /USP/UNICAMP
Carlos Henrique de Brito Cruz – Scientific Director (FAPESP)
New Drugs for Neglected Diseases
Drug Discovery to Control and Eradicate Malaria
Science for All: Urgent Needs
Sylvio Canuto – Dean of Research (USP)
Are Malaria, Chagas Disease and Leishmaniasis Neglected
Drug Discovery for the Most Neglected
Through the project and working with expert scientists from MMV the team will focus on delivering a candidate to treat malaria.
The compound should have the potential to be developed, in combination, to deliver a single exposure radical cure and prophylaxis or single exposure chemoprotection drug. MMV will provide quality lead molecules, aligned to a particular target product profile (TPP) of interest.
The goal of the project with DNDi is to deliver an optimized lead compound ready for preclinical and subsequently clinical development for the treatment of Chagas disease and/or leishmaniasis that addresses the significant deficiencies of current standard of care medications.
The Consortium will use the target product profiles (TPPs) developed by DNDi and its partners to ensure the deliverable is a compound that meets the needs of patients. The targeted clinical candidate will combine anti-protozoal efficacy with an acceptable safety profile and pharmacokinetics/physicochemical properties commensurate with oral delivery for testing against Chagas disease and leishmaniasis.
FAPESP – Rua Pio XI, 1500 – Alto da Lapa – São Paulo
Information – 11.3838-4362 | email@example.com
Parking suggestion – Rua Pio XI, 1650 | Av. São Gualter, 151 Rua Jorge Americano, 89